Abstract

Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.

Highlights

  • With almost 5 million new HIV infections and 3 million deaths from AIDS occurring every year worldwide, the development of a safe, effective, and accessible HIV vaccine has become one of the most urgent global public health needs

  • Women’s Concerns about Enrolling in HIV Vaccine Trials Efforts to enroll and retain women in trials begin by recognizing that their expectations and requirements for participation may be different from those of men

  • Supplying trial centers with counselors and staff who are sensitive to gender, class, and cultural barriers may improve women’s access to HIV vaccine trials

Read more

Summary

Policy Forum

Enrolling Women into HIV Preventive Vaccine Trials: An Ethical Imperative but a Logistical Challenge. The United Nations estimates that 17.5 million women between the ages of 15 and 49 years are living with HIV, accounting for nearly half of the 40.3 million infections worldwide [1] These figures reveal the increasingly female face of AIDS. Women’s Concerns about Enrolling in HIV Vaccine Trials Efforts to enroll and retain women in trials begin by recognizing that their expectations and requirements for participation may be different from those of men. Some cultural barriers identified in the recent HIV vaccine candidate trial in Kenya included women’s belief that a woman of childbearing age who uses contraceptives is giving her husband an excuse to look for another woman with whom to bear children [7]. Supplying trial centers with counselors and staff who are sensitive to gender, class, and cultural barriers may improve women’s access to HIV vaccine trials. Allowing flexible clinic hours to meet the specific needs of patients is one of many pragmatic solutions resulting from such sensitivity training

Fear of Adverse Events
Informed Consent
Barriers Faced by Sex Workers
Benefits of Participation
Researchers as Human Rights Advocates
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.